Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amantadine
Drug ID BADD_D00097
Description An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.
Indications and Usage For the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions.
Marketing Status approved
ATC Code N04BB01
DrugBank ID DB00915
KEGG ID D07441
MeSH ID D000547
PubChem ID 2130
TTD Drug ID D02KRS
NDC Product Code 11014-0245; 70482-075; 46708-246; 62332-246; 70482-076; 62332-586; 70482-170; 60687-422; 70482-085; 11014-0234; 46708-586
UNII BF4C9Z1J53
Synonyms Amantadine | 1-Aminoadamantane | 1 Aminoadamantane | Adamantylamine | Wiregyt | Amanta | Amanta-HCI-AZU | Amanta HCI AZU | AmantaHCIAZU | Amanta-Sulfate-AZU | Amanta Sulfate AZU | AmantaSulfateAZU | Amantadin AZU | AZU, Amantadin | Amantadin AL | AL, Amantadin | Amantadin Stada | Stada, Amantadin | Amantadin-neuraxpharm | Amantadin neuraxpharm | Amantadinneuraxpharm | Amantadin-ratiopharm | Amantadin ratiopharm | Amantadinratiopharm | Amantadina Juventus | Juventus, Amantadina | Amantadina Llorente | Llorente, Amantadina | Amantadine Hydrochloride | Hydrochloride, Amantadine | Amantadine Sulfate | Sulfate, Amantadine | Amixx | Cerebramed | Gen-Amantadine | Gen Amantadine | GenAmantadine | Infecto-Flu | Infecto Flu | InfectoFlu | Infex | Midantan | PMS-Amantadine | PMS Amantadine | PMSAmantadine | Symadine | Symmetrel | Endantadine | Mantadix | tregor | Viregyt | Adekin | Aman
Chemical Information
Molecular Formula C10H17N
CAS Registry Number 768-94-5
SMILES C1C2CC3CC1CC(C2)(C3)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Serotonin syndrome17.05.02.004; 15.05.04.016; 12.03.01.0410.000393%Not Available
Skin discolouration23.03.03.0050.001061%Not Available
Skin disorder23.03.03.007--Not Available
Skin lesion23.03.03.0100.000590%Not Available
Sleep disorder19.02.04.0010.001337%Not Available
Somnolence19.02.05.003; 17.02.04.0060.003734%
Speech disorder19.19.02.002; 17.02.08.003; 22.12.03.0270.001651%Not Available
Stupor19.02.05.004; 17.02.04.007--Not Available
Sudden visual loss06.02.10.011; 17.17.01.014--Not Available
Suicidal ideation19.12.01.0030.000865%
Tachycardia02.03.02.007--Not Available
Tachypnoea22.02.01.014--Not Available
Tension19.06.02.005--Not Available
Thrombosis24.01.01.0060.001061%Not Available
Tremor17.01.06.0020.001061%
Urethral disorder20.07.01.002--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary retention20.02.02.0110.000393%
Urinary tract disorder20.08.01.001--Not Available
Vision blurred17.17.01.010; 06.02.06.0070.001926%
Visual acuity reduced06.02.10.012; 17.17.01.011--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Withdrawal syndrome08.06.02.012; 19.07.06.0230.000786%Not Available
Mental status changes19.07.01.0010.000590%Not Available
Peripheral swelling02.05.04.015; 08.01.03.0530.003734%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.001730%Not Available
Corneal decompensation06.08.01.003--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal stiffness15.03.05.0270.001337%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages